223 related articles for article (PubMed ID: 14979498)
1. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
Oostenbrink JB; Rutten-van Mölken MP; Al MJ; Van Noord JA; Vincken W
Eur Respir J; 2004 Feb; 23(2):241-9. PubMed ID: 14979498
[TBL] [Abstract][Full Text] [Related]
2. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
Cheyne L; Irvin-Sellers MJ; White J
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009552. PubMed ID: 26391969
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol].
García Ruiz AJ; Leiva Fernández F; Martos Crespo F
Arch Bronconeumol; 2005 May; 41(5):242-8. PubMed ID: 15919004
[TBL] [Abstract][Full Text] [Related]
4. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
Cheyne L; Irvin-Sellers MJ; White J
Cochrane Database Syst Rev; 2013 Sep; (9):CD009552. PubMed ID: 24043433
[TBL] [Abstract][Full Text] [Related]
5. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
6. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
Rutten-van Mölken MP; Oostenbrink JB; Miravitlles M; Monz BU
Eur J Health Econ; 2007 Jun; 8(2):123-35. PubMed ID: 17370096
[TBL] [Abstract][Full Text] [Related]
7. Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan.
Hsu JY; Perng RP; Lu JY; Wu CP; Huang MS; Luh KT; Yang PC
J Formos Med Assoc; 2006 Sep; 105(9):708-14. PubMed ID: 16959618
[TBL] [Abstract][Full Text] [Related]
8. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease.
Hogan TJ; Geddes R; Gonzalez ER
Clin Ther; 2003 Jan; 25(1):285-97. PubMed ID: 12637127
[TBL] [Abstract][Full Text] [Related]
9. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.
Gani R; Griffin J; Kelly S; Rutten-van Mölken M
Prim Care Respir J; 2010 Mar; 19(1):68-74. PubMed ID: 20094687
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease].
Zheng JP; Kang J; Cai BQ; Zhou X; Cao ZL; Bai CX; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):363-7. PubMed ID: 17045014
[TBL] [Abstract][Full Text] [Related]
11. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
Vincken W; van Noord JA; Greefhorst AP; Bantje TA; Kesten S; Korducki L; Cornelissen PJ;
Eur Respir J; 2002 Feb; 19(2):209-16. PubMed ID: 11871363
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.
ZuWallack AR; ZuWallack RL
Expert Opin Pharmacother; 2004 Aug; 5(8):1827-35. PubMed ID: 15264997
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium: a potential replacement for ipratropium in patients with COPD.
Shukla VK
Issues Emerg Health Technol; 2002 Jul; (35):1-4. PubMed ID: 12195603
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease.
van Noord JA; Smeets JJ; Custers FL; Korducki L; Cornelissen PJ
Eur Respir J; 2002 Apr; 19(4):639-44. PubMed ID: 11998992
[TBL] [Abstract][Full Text] [Related]
16. [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease].
Schramm W; Haake D; Brandt A
Praxis (Bern 1994); 2005 Nov; 94(46):1803-10. PubMed ID: 16329401
[TBL] [Abstract][Full Text] [Related]
17. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
[TBL] [Abstract][Full Text] [Related]
18. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.
Casaburi R; Mahler DA; Jones PW; Wanner A; San PG; ZuWallack RL; Menjoge SS; Serby CW; Witek T
Eur Respir J; 2002 Feb; 19(2):217-24. PubMed ID: 11866001
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
Ma J; Zhou Z; Tang Y; Zhong N
Zhonghua Nei Ke Za Zhi; 2014 Dec; 53(12):964-8. PubMed ID: 25623564
[TBL] [Abstract][Full Text] [Related]
20. Methods to analyse cost data of patients who withdraw in a clinical trial setting.
Oostenbrink JB; Al MJ; Rutten-van Mölken MP
Pharmacoeconomics; 2003; 21(15):1103-12. PubMed ID: 14596629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
